Heterozygous deletion of chromosome 17p (17p) is one of the most frequent genomic
events in human cancers. Beyond the tumor suppressor TP53, the POLR2A gene encoding …

Current targeted cancer therapies are largely guided by mutations of a single gene, which
overlooks concurrent genomic alterations. Here, we show that RNASEH2B, RB1, and …

In the treatment of patients with locally advanced prostate cancer (PCa), androgen
deprivation therapy (ADT) significantly enhances the efficacy of radiotherapy by weakening …

The constitutively active androgen receptor (AR) splice variant 7 (AR-V7) plays an important
role in the progression of castration-resistant prostate cancer (CRPC). Although biomarker …

Prostate cancer remains a leading cause of cancer death in the United States (1). In 2017, it
was estimated that over 160,000 prostate cancer cases were diagnosed in the United …

Background While localized prostate cancer (PCa) can be effectively cured, metastatic
disease inevitably progresses to a lethal state called castration-resistant prostate cancer …

Prostate cancer (PCa) is one of the leading causes of cancer-related deaths among men.
Consequently, the identification of novel molecular targets for treatment is urgently needed …

The androgen receptor (AR) is a central driver of aggressive prostate cancer. After initial
treatment with androgen receptor signaling inhibitors (ARSi), reactivation of AR signaling …

Androgen receptor (AR) pathway inhibitors are the mainstay treatment for advanced prostate
cancer, but resistance to therapy is common. Here, we used a CRISPR activation screen in …

Purpose: The purpose of this study was to measure genomic changes that emerge with
enzalutamide treatment using analyses of whole-genome sequencing and RNA …